Trial Profile
A Phase Iib Randomised Double Blind, Placebo Controlled Parallel Group Study To Investigate The Efficacy And Safety Of Pf-00610355 Over 4 Weeks In Moderate Asthmatic Subjects
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 08 Feb 2019
Price :
$35
*
At a glance
- Drugs PF 610355 (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Pfizer
- 29 Jan 2019 Planned End Date changed from 1 Dec 2009 to 31 Dec 2009.
- 29 Jan 2019 Planned primary completion date changed from 1 Dec 2009 to 31 Dec 2009.
- 07 Nov 2011 Planned patient number is 356 according to European Clinical Trials Database.